ArticleHepatobiliary surgery and nutrition2026
Outcomes of highly urgent living donor liver transplantation in Korean national data.
Article in Hepatobiliary surgery and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Highly urgent living donor liver transplantation (HU-LDLT) is vital for treating acute liver failure (ALF), acute-on-chronic liver failure (ACLF), and critically ill cirrhotic patients in life-threatening scenarios. The purpose of our study was to identify the characteristics of HU-LDLT patients, compare the outcomes of HU-LDLT patients with those of elective LDLT patients, and determine the risk factors that can influence the outcomes of HU-LDLT. Methods: We retrospectively analyzed Korean Network for Organ Sharing (KONOS) data for consecutive HU-LDLT patients between 2017 and 2021. For comparison with the HU-LDLT group, patients who received elective LDLT except HU-LDLT at Samsung Medical Center during the same period were analyzed as the control group. Results: The most common reasons for HU-LDLT were hepatic encephalopathy, a model for end-stage liver disease (MELD) score ≥35, and uncontrolled varix bleeding. Among the 419 HU-LDLT patients, 53 (12.6%) were pediatric. The cumulative 1-, 3-, and 5-year overall survival rates were 82.4%, 78.3%, and 74.8%, respectively, in the adult HU-LDLT group. The 1-year overall survival rate was 86.1% in the pediatric HU-LDLT group. The presence of chronic kidney disease, pre-transplant ventilator care, high pre-transplant MELD score, and re-transplantation were closely related to mortality in the adult group. Only hepatorenal syndrome (HRS) was a strong risk factor for graft failure in the adult group. The graft and overall survival in the adult HU-LDLT group were significantly lower than those in the control group. Conclusions: High MELD scores, hepatic encephalopathy, and bleeding are the main reasons for HU-LDLT applications in Korea. Graft and overall survival curves in the HU-LDLT group are lower than in the elective LDLT group, but the HU-LDLT outcomes are considered acceptable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.